Invivyd (IVVD) Shares Outstanding (Diluted Average) (2021 - 2025)
Invivyd posted quarterly Shares Outstanding (Diluted Average) of $172.2 million for Q4 2025, up 45.26% year-on-year from $118.6 million in Q4 2024, and up 1.2% on a QoQ basis from $170.2 million in Q3 2025.
Invivyd (IVVD) has 5 years of Shares Outstanding (Diluted Average) data on file, last reported at $172.2 million in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 45.26% year-over-year to $172.2 million; the trailing twelve-month figure through Dec 2025 stood at $172.2 million (up 45.26% YoY), and the FY2025 full-year result was $172.2 million, up 45.26% from the prior year.
- Shares Outstanding (Diluted Average) for Q4 2025 stood at $172.2 million, up from $170.2 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $172.2 million in Q4 2025 and bottomed at $249769.0 in Q2 2021.
- The 5-year median for Shares Outstanding (Diluted Average) is $109.5 million (2023), against an average of $106.8 million.
- The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) surged 43147.58%; it then grew 0.55% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $42.6 million in 2021, then surged by 154.02% to $108.3 million in 2022, then gained by 1.16% to $109.5 million in 2023, then advanced by 8.24% to $118.6 million in 2024, then jumped by 45.26% to $172.2 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $172.2 million (Q4 2025), $170.2 million (Q3 2025), and $120.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 172.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 172.21 Mn |
| Sep 30, 2025 | 170.17 Mn |
| Jun 30, 2025 | 120.02 Mn |
| Mar 31, 2025 | 119.88 Mn |
| Dec 31, 2024 | 118.56 Mn |
| Sep 30, 2024 | 119.50 Mn |
| Jun 30, 2024 | 119.36 Mn |
| Mar 31, 2024 | 115.62 Mn |
| Dec 31, 2023 | 109.53 Mn |
| Sep 30, 2023 | 109.75 Mn |
| Jun 30, 2023 | 109.45 Mn |
| Mar 31, 2023 | 108.79 Mn |
| Dec 31, 2022 | 108.27 Mn |
| Sep 30, 2022 | 108.15 Mn |
| Jun 30, 2022 | 108.02 Mn |
| Mar 31, 2022 | 107.87 Mn |
| Dec 31, 2021 | 42.62 Mn |
| Sep 30, 2021 | 61.30 Mn |
| Jun 30, 2021 | 249,769.00 |